Levodopa and orphenadrine hydrochloride in parkinsonism
In Parkinsonian patients on maximum tolerated doses of levodopa, a double-blind, cross-over trial showed that greater benefit was conferred by additional orphenadrine hydrochloride than by placebo. Further observations suggest that the benefit conferred by supplemental orphenadrine is lost if the drug is withdrawn either suddenly or gradually. The greatest improvements were seen in balance, posture, handwriting, performance of domestic tasks, dressing and feeding.